LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Regulus Therapeutics Inc

Closed

8.21 1.36

Overview

Share price change

24h

Current

Min

8.19

Max

8.23

Key metrics

By Trading Economics

Income

3.2M

-9.6M

Sales

340K

340K

EPS

-0.15

Profit margin

-2,833.529

Employees

34

EBITDA

2.2M

-11M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+8.64% upside

Dividends

By Dow Jones

Next Earnings

6 sie 2025

Market Stats

By TradingEconomics

Market Cap

315M

550M

Previous open

6.85

Previous close

8.21

Regulus Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

30 kwi 2025, 16:35 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Regulus Shares Surge on $1.7 Billion Acquisition by Novartis

30 kwi 2025, 11:55 UTC

Acquisitions, Mergers, Takeovers

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Billion

30 kwi 2025, 11:54 UTC

Acquisitions, Mergers, Takeovers

Novartis to Acquire Regulus in $1.7 Billion Deal

27 maj 2025, 12:04 UTC

Acquisitions, Mergers, Takeovers

Correct: Novartis Will Offer $7.00 in Cash Per Share

27 maj 2025, 12:01 UTC

Acquisitions, Mergers, Takeovers

Novartis: Offer Will Expire on June 24

27 maj 2025, 12:00 UTC

Acquisitions, Mergers, Takeovers

Novartis Will Offer $0.001 Per Share

27 maj 2025, 11:59 UTC

Acquisitions, Mergers, Takeovers

Novartis: Offer Is to Acquire All Outstanding Shares of Regulus Therapeutics's Common Stock

27 maj 2025, 11:59 UTC

Acquisitions, Mergers, Takeovers

Novartis: Redwood Merger Sub Inc. Is an Indirect Wholly Owned Subsidiary of Novartis

27 maj 2025, 11:58 UTC

Acquisitions, Mergers, Takeovers

Novartis: Redwood Merger Sub Inc. Has Commenced a Tender Offer

27 maj 2025, 11:57 UTC

Acquisitions, Mergers, Takeovers

Novartis Announces Commencement of Tender Offer to Buy Regulus Therapeutics

30 kwi 2025, 11:40 UTC

Acquisitions, Mergers, Takeovers

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Bln

30 kwi 2025, 11:39 UTC

Acquisitions, Mergers, Takeovers

Novartis to Acquire Regulus in $1.7B Deal

30 kwi 2025, 11:16 UTC

Acquisitions, Mergers, Takeovers

Novartis: Transaction Is Expected to Close in Second Half of 2025

30 kwi 2025, 11:15 UTC

Acquisitions, Mergers, Takeovers

Novartis: Regulus Therapeutics Is U.S. Biotech Focused on microRNA Therapeutics

30 kwi 2025, 11:14 UTC

Acquisitions, Mergers, Takeovers

Novartis: Transaction Includes USD0.8B Upfront Payment, Potential Additional USD 0.9B Payment

30 kwi 2025, 11:13 UTC

Acquisitions, Mergers, Takeovers

Novartis to Buy Regulus Therapeutics

Peer Comparison

Price change

Regulus Therapeutics Inc Forecast

Price Target

By TipRanks

8.64% upside

12 Months Forecast

Average 8.8 USD  8.64%

High 11 USD

Low 7 USD

Based on 6 Wall Street analysts offering 12 month price targets forRegulus Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

6 ratings

1

Buy

5

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Regulus Therapeutics Inc

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.